Alaric DeArment on Muck Rack

Alaric DeArment

Verified
As seen in: Citeline, Scrip, Medium, Forbes, Aol, New York Daily News, The Hill, Flipboard, Salon, The Times of Israel, Yahoo, South Florida Sun Sentinel and

Get in touch with Alaric

Contact Alaric, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

AstraZeneca Builds Up Oncology As It Looks To 2030

|
By Alaric DeArment 
| Scrip
At an ASCO analyst briefing, the company highlighted programs in oncology and other disease areas that will help it meet a goal of bringing in $80bn in sales by 2030. Oncology is an integral part of AstraZeneca’s aim to reach $80bn in revenue by the start of the next decade, along with other disease areas, and the company used an analyst meeting at the American Society of Clinical Oncology (ASCO) meeting to review its late-stage oncology data.
Open in Who Shared Issue with article?

Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis

|
By Alaric DeArment 
| Scrip
The drugmaker plans to seek approval during its 2026 fiscal year and, pending a positive FDA decision, launch in the first half of calendar year 2027. Takeda announced topline results from the LATITUDE Atlas study. (Shutterstock) Takeda has notched an important win for zasocitinib, its TYK2 inhibitor, in moderate-to-severe plaque psoriasis among adult patients, with topline Phase III results showing the drug is superior to Bristol Myers Squibb’s Sotyktu (deucravacitinib).
Open in Who Shared Issue with article?

J&J Opts Not To Follow The Oncology Crowd

|
By Alaric DeArment 
| Scrip
J&J exec Mark Wildgust sat down with Scrip at ASCO to discuss the drugmaker’s swing-for-the-fences approach to drug development. Nobody likes being second place, but Johnson & Johnson has made consciously avoiding “me-too” approaches and products that offer only incremental improvement while pursuing high-impact research central to its oncology drug-development strategy, which it showcased at the recent American Society of Clinical Oncology (ASCO) meeting.
Open in Who Shared Issue with article?
See all 2,534 licensed articles (2,535 Total)

Actions

Share this page

Get in touch with Alaric

Contact Alaric, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified